ReviewThe pharmacogenomics journal2018
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.
Open access · bronzeAbstract readReview
In one paragraph
Review in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- Association ofGenes · 2024Article
- Predicting treatment response to methotrexate: are we closer to solving the enigma?Rheumatology (Oxford, England) · 2024Article
- Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis.Rheumatology (Oxford, England) · 2024Article
- Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis.RMD open · 2024Article
- Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity.Biomolecules · 2023Article
- DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis.Biomedicines · 2023Review
- Pharmacogenetic Sex-Specific Effects of Methotrexate Response in Patients with Rheumatoid Arthritis.Pharmaceutics · 2023Article
- -Omic Approaches and Treatment Response in Rheumatoid Arthritis.Pharmaceutics · 2022Review
- Functional coding haplotypes and machine-learning feature elimination identifies predictors of Methotrexate Response in Rheumatoid Arthritis patients.EBioMedicine · 2022Article
- Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.International journal of molecular sciences · 2021Review
- The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Methotrexate Treatment of Newly Diagnosed RA Patients Is Associated With DNA Methylation Differences at Genes Relevant for Disease Pathogenesis and Pharmacological Action.Frontiers in immunology · 2021Observational
- Rheumatology in the era of precision medicine: synovial tissue molecular patterns and treatment response in rheumatoid arthritis.Current opinion in rheumatology · 2021Review
- Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics.Biomolecules · 2020Review
- Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio.Rheumatology and therapy · 2020Article
- Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases.Genome medicine · 2020Article
- Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile.ACS medicinal chemistry letters · 2020Article
- Methotrexate and its mechanisms of action in inflammatory arthritis.Nature reviews. Rheumatology · 2020Review
- Detection and Comparative Analysis of Methylomic Biomarkers of Rheumatoid Arthritis.Frontiers in genetics · 2020Article
- Adding value to real-world data: the role of biomarkers.Rheumatology (Oxford, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 14 institutions in 6 countries.
John C TaylorLeeds Institute of Cancer and Pathology, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID http://orcid.org/0000-0002-2518-5799
Tim BongartzVanderbilt University, Nashville, TN, USA.
Jonathan MasseyArthritis Research UK Centre for Genetics and Genomics, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Borbala MifsudClinical Pharmacology, William Harvey Research Institute, Queen Mary University, London, UK.
Athina SpiliopoulouCentre for Population Health Sciences, Usher Institute, University of Edinburgh Old Medical School, Teviot Place, Edinburgh, UK.ORCID http://orcid.org/0000-0002-5929-6585
Ian C ScottResearch Institute for Primary Care and Health Sciences, Primary Care Sciences, Keele University and Department of Rheumatology, Haywood Hospital, High Lane, Burslem, Staffordshire, UK.
Jianmei WangRoche Products, Welwyn Garden City, UK.
Michael MorganLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Darren PlantArthritis Research UK Centre for Genetics and Genomics, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Marco ColomboCentre for Population Health Sciences, Usher Institute, University of Edinburgh Old Medical School, Teviot Place, Edinburgh, UK.
Peter OrchardPharmatics Ltd., 9, Little France Road, Edinburgh, UK.
Sarah TwiggLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Iain B McInnesInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Duncan PorterInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Jane E FreestonLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Jackie L NamLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Heather J CordellInstitute of Genetic Medicine, Newcastle University, Newcastle, UK.
John D IsaacsMusculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and NIHR Newcastle Biomedical Research Centre in Ageing and Long Term Conditions, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Jenna L StrathdeeLeeds Institute of Cancer and Pathology, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Donna ArnettUniversity of Kentucky College of Public Health, Lexington, KY, 40536, USA.
Maria J H de HairUniversity Medical Center Utrecht, Utrecht, The Netherlands.
Paul P TakAcademic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Stella AslibekyanDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ronald F van VollenhovenRheumatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Leonid PadyukovRheumatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-2950-5670
S Louis BridgesDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Costantino PitzalisBarts and The London School of Medicine & Dentistry, William Harvey Research Institute, Queen Mary University, London, UK.
Andrew P CopeAcademic Department of Rheumatology, Faculty of Life Sciences and Medicine, King's College London, London, UK.
Suzanne M M VerstappenArthritis Research UK Centre for Genetics and Genomics, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
Paul EmeryLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Michael R BarnesBarts and The London School of Medicine & Dentistry, William Harvey Research Institute, Queen Mary University, London, UK.ORCID http://orcid.org/0000-0001-9097-7381
Felix AgakovPharmatics Ltd., 9, Little France Road, Edinburgh, UK.
Paul McKeigueCentre for Population Health Sciences, Usher Institute, University of Edinburgh Old Medical School, Teviot Place, Edinburgh, UK.
Taisei MushirodaRIKEN Center for Integrative Medical Sciences, Tokyo, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Sciences, Tokyo, Japan.
Richard WeinshilboumMayo Clinic, Rochester, MN, USA.
Anne BartonArthritis Research UK Centre for Genetics and Genomics, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-3316-2527
Ann W MorganLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. a.w.morgan@leeds.ac.uk.ORCID http://orcid.org/0000-0003-1109-624X
Jennifer H BarrettLeeds Institute of Cancer and Pathology, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.ORCID http://orcid.org/0000-0002-1720-7724
MATURA
and PAMERA
Consortia
University of Leeds · GBKarolinska University Hospital · SEManchester Academic Health Science Centre · GBUniversity of Glasgow · GBKing's College London · GBRIKEN Center for Integrative Medical Sciences · JPRoche (United Kingdom) · GBUniversity of Alabama at Birmingham · USUniversity of Kentucky · USWilliam Harvey Research Institute · GBMayo Clinic in Arizona · USNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNIHR Leeds Musculoskeletal Biomedical Research Unit · GBVanderbilt University · US
Funding
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8MPredictors of Treatment Response in Early Aggressive RAR01AR052658 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BRIDGES, S LOUIS · 2004 to 2007
$1.2MArthritis Research UK 18387Arthritis Research UK 18475Arthritis Research UK 19739Arthritis Research UK 20385Medical Research Council G0800648Medical Research Council G1001518Medical Research Council MR/K015346/1Medical Research Council MR/L01629X/1Medical Research Council MR/L016311/1NIAMS NIH HHS R01 AR052658NIGMS NIH HHS U19 GM061388
Abstract
Methotrexate (MTX) monotherapy is a common first treatment for rheumatoid arthritis (RA), but many patients do not respond adequately. In order to identify genetic predictors of response, we have combined data from two consortia to carry out a genome-wide study of response to MTX in 1424 early RA patients of European ancestry. Clinical endpoints were change from baseline to 6 months after starting treatment in swollen 28-joint count, tender 28-joint count, C-reactive protein and the overall 3-component disease activity score (DAS28). No single nucleotide polymorphism (SNP) reached genome-wide statistical significance for any outcome measure. The strongest evidence for association was with rs168201 in NRG3 (p = 10
Indexed as
Genome-Wide Association StudyAntirheumatic AgentsArthritis, RheumatoidC-Reactive ProteinHumansMethotrexateNeuregulinsSeverity of Illness IndexTranscription FactorsAntirheumatic AgentsC-Reactive ProteinMethotrexateNeuregulinsNRG3 protein, humanTranscription FactorsZMIZ1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.